Axsome Therapeutics Stock News

Axsome Therapeutics (AXSM) has been struggling lately, but the selling pressure may be coming to an end soon.

Company to host conference call today at 8:00 AM Eastern

After a fantastic run-up, investors are now losing faith in this emerging biotech's stock.

The stock price of Axsome Therapeutics, a biopharmaceutical company focused on developing novel therapies for central nervous system conditions, has seen a 19% drop over the last twenty-one trading da

NEW YORK, July 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Axsome Therapeutics, Inc. ("Axsome" or the "Company") (NASDAQ: AXSM). Such investors are ad

The FDA rescinds Breakthrough Therapy designation for Axsome's (AXSM) pipeline candidate, AXS-12. The company is developing AXS-12 for the potential treatment of cataplexy in narcolepsy patients.

NEW YORK, July 14, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Axsome Therapeutics, Inc. ("Axsome" or the "Company") (NASDAQ: AXSM).  Such investors are a

The FDA took back a beneficial designation but management isn't changing its plans.

This biotech has significant upside left.

The stock price of Axsome Therapeutics, a biopharmaceutical company focused on developing novel therapies for central nervous system conditions, has seen a 13% rise over the last twenty-one trading se

Axsome (AXSM) concludes a favorable pre-NDA meeting with the FDA for AXS-14, which is being developed as a treatment of fibromyalgia. The company will file an NDA in the fourth quarter of 2022.

After a pre-NDA meeting with FDA, Axsome Therapeutics Inc (NASDAQ: AXSM) has announced its plan to submit a marketing application seeking approval for AXS-14 to manage fibromyalgia. The submission

Progress in these companies' drug development pipelines should give shareholders plenty to look forward to.

Axsome has a PDUFA on August 22.

Axsome (AXSM) reports narrower-than-expected loss for the first quarter of 2021. The company is gearing up to launch its first commercial product, AXS-05, following a potential approval.